Reflow Medical, Inc. news

 Reflow Medical, Inc., a California-based medical device company, has completed enrollment in the DEEPER LIMUS clinical trial (NCT04162418) to evaluate the Temporary Spur Stent System, a patented device designed to treat long, diffuse and severely calcified infrapopliteal disease. The system allows for uniform expansion of the stent to maximize lumen diameter and may reduce acute vessel recoil and d

Reflow Medical, Inc. announces that it has completed patient enrollment in the DEEPER OUS clinical trial (NCT03807531) for the company’s Temporary Spur Stent System, a novel device that features a retrievable stent designed for complex infrapopliteal disease. 

106 patients have now been enrolled in the prospective, nonrandomized trial in multiple centers in Europe and New Zealand. Intended for

Reflow Medical, Inc., a California- based medical device company, announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved the Wingman™ CTO Catheter. Reflow Medical has partnered with Century Medical, Inc. (CMI), a leading medical device distributor based in Tokyo, to introduce the Wingman CTO Catheter in Japan.

The Wingman Catheter crosses peripheral CTOs using an extendable beveled tip. The physician controls the advancement and activation of

Reflow Medical, Inc., a California-based medical device company, introduces the Reflow™ Spex™ LP (Low Profile) 0.014 and 0.018-inch reinforced support catheters. The new Spex LP is engineered to provide the lowest profile tip for accessing and crossing the tightest and most complex lesions with a supportive system. It also features three radiopaque markers that enhance visibility on imaging. The Spex LP can be combined with the Reflow Spex™ 35 for more robust support.

Reflow Medical, Inc., a California-based medical device company, has enrolled the first patients in A Non-Randomized Pilot Study of the Temporary Spur Stent System for the Treatment of Lesions Located in the InfraPoplitEal Arteries Using a LIMUS-base Drug-coated Balloon (DEEPER LIMUS). The OUS single center clinical trial (NCT04162418) is expected to enroll up to 30 participants and last approximately six months. It will follow primary and secondary endpoints for safety and effi

Reflow Medical is taking steps to prevent the community spread of COVID-19 and to ensure the safety of our employees. We are adapting to the changing environment as we continue to design and develop medical devices used in life-saving treatments for cardiovascular disease.

We want to express our gratitude to those in the healthcare community, including our clinical partners, who are serving patients during this difficult time. We also want to thank our employees for their dedication a

Reflow Medical, Inc., a California-based medical device company, has announced that they have received clearance from the FDA for an expanded indication for the Wingman™ Crossing Catheter after completing the Wing-IT clinical trial. The Wingman Catheter crosses peripheral CTOs using an extendable beveled tip that creates a channel to help penetrate, or cross, the occlusion with a guidewire, enabling further treatment of the lesion with therapeutic devices.

The Wing-IT CTO clinic